Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications. TCB is responsible for development of all targets through Phase 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.Financial terms of the agreement include a $16 million upfront payment and subsequent potential R&D and commercial milestone payments. TCB is also eligible to receive undisclosed tiered royalties on product sales.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Dec 07, 2017
Projected Implementation:
Q4, 2017
Relevance Tracked Until:
Q2, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Car T-cell, Cancer Immunotherapy